C. RANK ligand produced by osteoblast-lineage and stromal cells
Why this is correct
Denosumab is a monoclonal antibody directed against RANK ligand (RANKL). RANKL normally binds RANK on osteoclast precursors, supporting their differentiation, activation and survival; its inhibition decreases osteoclast-mediated bone resorption and can improve bone density and fracture outcomes in indicated patients. Osteoprotegerin is an endogenous decoy receptor for RANKL. Denosumab discontinuation without planned subsequent antiresorptive management can lead to rebound bone turnover and multiple vertebral fractures, a critical clinical safety issue.
Why each option is correct or incorrect
Calcitonin can inhibit osteoclast activity but is not denosumab's target.
PTH regulates calcium and bone remodeling but is not directly neutralized by denosumab.
Correct: the antibody neutralizes RANKL and thereby blocks osteoclast precursor stimulation.
Osteoprotegerin is a natural protective decoy receptor; denosumab imitates its RANKL-blocking function rather than blocking OPG.
High-yield notes
- Denosumab blocks RANKL and inhibits osteoclast formation and survival.
- Osteoprotegerin naturally sequesters RANKL.
- Stopping denosumab can cause rebound bone resorption and vertebral fractures without planned follow-on therapy.
RANKL stimulates osteoclasts; denosumab is an anti-RANKL antibody.
Do not treat denosumab as interchangeable with bisphosphonates at discontinuation; a transition plan is essential.